Crispr Therapeutics: FDA Filing on Sickle Cell Gene Therapy Is Almost Done

An approval filing for a breakthrough treatment of sickle cell disease should be done by March, Crispr Therapeutics said, highlighting the company’s lead in a competitive area of medical research and ...

Why Pfizer Is Pulling Back on Research Into Rare Disease, Gene Therapy

Pfizer is planning to pull back on early-stage research into treatments for rare diseases, including the development of new viral-based gene therapies, the company told employees on Thursday afternoon...

25 Stocks That Could Rise on a Short Squeeze

Investors betting against electric-vehicle stocks take note: Five of 25 stocks that short-selling research firm S3 Partners identified this month as being at risk of a short squeeze are in the EV busi...

It’s Time to Bargain Hunt. 27 Picks to Beat the Stock Market From Barron’s Roundtable Experts.

“There is no easier way to make money in the market than to buy a great company under pressure due to short-term concerns.” So said the newest member of the Barron’s Roundtable, David Giroux of T. Row...

Las Vegas Sands Stock Could See Better Luck Ahead

Text size These reports, excerpted and edited by Barron’s, were issued recently by investment and research firms. The reports are a sampling of analysts’ thinking; they should not be considered the vi...